TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
CRBU

Caribou Biosciences Inc

Healthcare · Biotechnology

0.3772$ -3.5% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Caribou Biosciences Inc (CRBU)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 96.0% of the shares are freely tradable; institutional investors hold 44.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 44.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 8.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 96.0%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 12.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 107Mio.

Largest Shareholders

Institutions

Institutions CRBU
Name Stake (%) Shares Change (%) Date
BlackRock Inc 7.29 7,815,843 +264.7 06/30/2026
Pfizer Inc 4.38 4,690,431 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.93 4,208,568 +11.7 06/30/2026
Mackenzie Investments 3.41 3,650,796 +287.2 06/30/2026
Renaissance Technologies Corp 2.59 2,773,545 +7.1 06/30/2026
Kynam Capital Management, LP 2.34 2,503,302 +0.0 06/30/2026
Geode Capital Management, LLC 2.22 2,374,894 +133.3 06/30/2026

Funds

Funds CRBU
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.81 3,013,973 +0.0 09/30/2026
iShares Russell 2000 ETF 2.09 2,241,932 -0.4 10/29/2026
ACATIS Datini Valueflex Fonds A 1.87 2,000,000 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?